Loading search results
CheckMate 74W
A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)
Sponsor study identifier
interventional
26
19 countries
107
Study Start
September 14, 2020
Actual (reported)Primary Completion
December 12, 2023
Actual (reported)Study Completion
December 12, 2023
Actual (reported)The purpose of this study is to evaluate the safety and tolerability of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 12, 2023
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 7, 2020
Actual (reported)April 9, 2020
Actual (reported)September 14, 2020
Actual (reported)December 12, 2023
Actual (reported)December 12, 2023
Actual (reported)November 26, 2024
Actual (reported)Number of Participants With Adverse Events
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Number of Participants With Serious Adverse Events (SAEs)
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose that results in death, Is life-threatening (defined as an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe) or requires inpatient hospitalization or causes prolongation of existing hospitalization, or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is an important medical event.
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Number of Participants Who Died
Number of participants who died due to any cause are summarized.
From first dose and 100 days after last dose of study therapy (up to approximately 27 months)
Number of Participants With Adverse Events Leading to Study Drug Discontinuation
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Number of Participants With Worst Grade (Grade 3/4) Laboratory Results
Laboratory results were graded using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (Grade 3 =Severe, Grade 4 = Life-threatening). Highest grade measured for hemoglobin and albumin was Grade 3.
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
Blood samples were collected for specific thyroid test.
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
Number of Participants With Clinical Laboratory Abnormalities in Specific Liver Tests
Blood samples were collected for specific liver tests.
From first dose and 30 days after last dose of study therapy (up to approximately 25 months)
TACE (Trans-arterial ChemoEmbolization)
Specified dose on specified days
Specified dose on specified days
Local Institution - 0189
Coronado, California, 92118, United States
Local Institution
Washington D.C., District of Columbia, 20007, United States
Local Institution - 0005
Louisville, Kentucky, 40202, United States
Local Institution - 0059
Louisville, Kentucky, 40217, United States
Local Institution - 0109
Dallas, Texas, 75203, United States
Local Institution
Wollongong, New South Wales, 2500, Australia
Local Institution - 0037
Birtinya, Queensland, 4575, Australia
Bristol-Myers Squibb
Bristol-Myers Squibb
26 participants (actual enrollment reported by the registry).
First Submitted
April 7, 2020
First Posted
April 9, 2020
Study Start
September 14, 2020
Actual (reported)TACE (Trans-arterial ChemoEmbolization)
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
Local Institution - 0010
Adelaide, South Australia, 5000, Australia
Local Institution - 0001
Melbourne, Victoria, 3065, Australia
Local Institution - 0139
Murdoch, Western Australia, 6150, Australia
Local Institution - 0026
Graz, 8036, Austria
Local Institution - 0013
Sankt Pölten, 3100, Austria
Local Institution
Vienna, 1100, Austria
Local Institution - 0078
West Springfield, 1090, Austria
Local Institution - 0048
Wiener Neustadt, 2700, Austria
Local Institution - 0020
Brussels, 1200, Belgium
Local Institution
Federal District, 72115700, Belgium
Local Institution - 0053
Ghent, 9000, Belgium
Local Institution - 0050
Plainfield, 1070, Belgium
Local Institution - 0039
Québec, Quebec, G1R 2J6, Canada
Local Institution - 0184
Beijing, Beijing Municipality, 100034, China
Local Institution
Guangzhou, Guangdong, 510060, China
Local Institution
Guangzhou, Guangdong, 510095, China
Local Institution
Tianjin, Hebei, 300060, China
Local Institution - 0196
Nanjing, Jiangsu, 210009, China
Local Institution - 0176
Nanchang, Jiangxi, 330006, China
Local Institution
Shenyang, Liaoning, 110042, China
Local Institution - 0209
Xi'an, Shan3xi, 710100, China
Local Institution - 0151
Shanghai, Shanghai Municipality, 200040, China
Local Institution
Chengdu, Sichuan, 610041, China
Local Institution
Hangzhou, Zhejiang, 310003, China
Local Institution
Hangzhou, Zhejiang, 310022, China
Local Institution - 0055
Olomouc, 779 00, Czechia
Local Institution
Prague, 15000, Czechia
Local Institution - 0014
Lille, Mount, 59037, France
Local Institution - 0132
Caen, 14033, France
Local Institution - 0021
Clichy, 92110, France
Local Institution - 0064
Dijon, 21000, France
Local Institution - 0082
Englewood, 34295, France
Local Institution - 0052
La Tronche, 38700, France
Local Institution - 0061
Marseil, 13285, France
Local Institution - 0087
Nantes, 44093, France
Local Institution - 0012
Nice, 6202, France
Local Institution - 0093
Paris, 75013, France
Local Institution - 0046
Reims, 51092, France
Local Institution - 0094
Villejuif, 94805, France
Local Institution - 0035
Göttingen, 37075, Germany
Local Institution
Hanover, 30625, Germany
Local Institution
Heidelberg, 69120, Germany
Local Institution - 0071
Leipzig, 4103, Germany
Local Institution - 0004
Hong Kong, 0, Hong Kong
Local Institution - 0045
Hong Kong, 0, Hong Kong
Local Institution - 0015
Orbassano, TO, 10043, Italy
Local Institution
Messina, 98124, Italy
Local Institution - 0025
Milan, 20122, Italy
Local Institution
Monserrato, 9042, Italy
Local Institution
Parma, 43126, Italy
Local Institution
Roma, 78584, Italy
Local Institution - 0076
Siena, 53100, Italy
Local Institution - 0070
Vicenza, 36100, Italy
Local Institution - 0108
Chiba, Chiba, 260-8677, Japan
Local Institution - 0122
Matsuyama, Ehime, 790-0024, Japan
Local Institution - 0148
Sapporo, Hokkaido, 060-0033, Japan
Local Institution - 0118
Kanazawa, Ishikawa-ken, 9208641, Japan
Local Institution - 0120
Yokohama, Kanagawa, 2320024, Japan
Local Institution - 0113
Yokohama, Kanagawa, 241-0815, Japan
Local Institution - 0115
Kyoto, Kyoto, 602-0841, Japan
Local Institution - 0127
Abeno-ku, Osaka, 545-8586, Japan
Local Institution - 0125
Izunokuni-Shi, Shizuoka, 4102295, Japan
Local Institution - 0116
Minato-ku, Tokyo, 105-8470, Japan
Local Institution - 0128
Minato-ku, Tokyo, 105-8470, Japan
Local Institution - 0121
Musashino-shi, Tokyo, 180-8610, Japan
Local Institution - 0119
Hiroshima, 734-8551, Japan
Local Institution - 0117
Osaka, 589-8511, Japan
Local Institution - 0123
Saitama, 350-0495, Japan
Local Institution
Warsaw, 02-034, Poland
Local Institution - 0049
San Juan, 00902, Puerto Rico
Local Institution - 0016
Barnaul, 656049, Russia
Local Institution - 0077
Saint Petersburg, 197758, Russia
Local Institution - 0009
Saint Petersburg, 198255, Russia
Local Institution - 0027
Singapore, 119074, Singapore
Local Institution - 0089
Singapore, 217562, Singapore
Local Institution - 0011
Singapore, 308433, Singapore
Local Institution - 0114
Busan, 49241, South Korea
Local Institution - 0135
Daegu, 41944, South Korea
Local Institution - 0047
Gyeongsangnam-do, 050612, South Korea
Local Institution - 0097
Hwasun-Gun, 58128, South Korea
Local Institution - 0161
Seoul, 03080, South Korea
Local Institution - 0186
Seoul, 05505, South Korea
Local Institution - 0160
Seoul, 06351, South Korea
Local Institution - 0164
Seoul, 120-752, South Korea
Local Institution - 0023
Alicante, 03010, Spain
Local Institution - 0092
Córdoba, 14004, Spain
Local Institution - 0101
Madrid, 28007, Spain
Local Institution - 0183
Madrid, 28027, Spain
Local Institution - 0084
Madrid, 28034, Spain
Local Institution - 0018
Madrid, 28041, Spain
Local Institution - 0099
Pamplona, 31008, Spain
Local Institution - 0131
Sabadell, 8208, Spain
Local Institution - 0102
Santiago de Compostela, 15706, Spain
Local Institution - 0136
Buzi, 613, Taiwan
Local Institution - 0141
Kaohsiung City, 807, Taiwan
Local Institution - 0030
Taichung, 40447, Taiwan
Local Institution - 0057
Taichung, 40705, Taiwan
Local Institution - 0029
Tainan, 704, Taiwan
Local Institution - 0002
Taipei, 10002, Taiwan
Local Institution - 0044
Tapei, 11217, Taiwan
Primary Completion
December 12, 2023
Actual (reported)Study Completion
December 12, 2023
Actual (reported)Last Updated
November 26, 2024
Results First Posted
November 26, 2024
Record last verified: 2024-11
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: